🟢 Moderna Inc is trading 5.9% up today as flu vaccine study shows superior immunity

Moderna Inc is trading 5.9% up now at $55.22 after a study published in Nature Immunology showed its investigational flu vaccine, mRNA-1010, generated broader and more durable immunity than standard flu shots.

• The data suggests that Moderna’s mRNA platform may offer significant advantages in long-term efficacy and immune response over traditional influenza vaccines.
• The stock's move stands out against a mixed broader market, indicating that investors are re-rating the company’s non-COVID pipeline and long-term platform potential.